目的

探讨乳腺癌演变中新生血管表达状况,旨在选择乳腺癌发生发展中新生血管的特异性标记物。

方法

采用免疫组化(SP)法,分别以CD105、FⅧ、CD31、CD34 为标记,对100 例乳腺不同病变组织,包括乳腺导管上皮不典型增生(ADH)、导管内癌(DCIS)、微浸润导管癌(MDC)各20 例,40 例非特殊类型浸润型导管癌(IDC,NOS),计算微血管密度(MVD)。

结果

ADH、DCIS、MDC 和IDC(NOS)中,CD105标记的MVD 分别为8.25 ±5.78、10.05 ±4.23、25.35 ±7.62 和37.33 ±5.86,FⅧ标记的MVD 分别为10.60 ±8.99、16.60 ±3.47、16.90 ±5.62 和17.90 ±5.62,CD31 标记的MVD 分别为16.80 ±3.90、19.40 ±4.58、20.74 ±6.67 和22.74 ±6.67,CD34 标记的MVD 分别为14.40 ±12.82、25.20 ±5.39、26.32 ±4.89 和40.32 ±4.89,仅CD105 标记的MVD 各组间两两比较差异有统计学意义( P ＜0.05)。

结论

CD105 标记MVD 用来评估乳腺癌发生发展中的新生血管表达,可能更具价值,这将为今后抗血管生成的治疗提供理论依据。

Objective

To detect the changes of new vessels in the evolution of breast carcinoma so as to select a better new vessel endothelial cells marker.

Methods

By using immunohistochemistry the breast tissues of 100 patients including 20 cases of atypical ductal hyperplasia (ADH), 20 cases of ductal carcinoma in situ(DCIS),20 cases of microductal carcinoma (MDC) and 40 cases of infiltrating ductal carcinoma (IDC, NOS)were stained with anti-CD105, FⅧ, CD31 and CD34 antibodies, then the microvessel density (MVD) was calculated.

Results

The MVD of CD105 was 8.25 ±5.78,10.05 ±4.23,25.35 ±7.62 and 37.33 ±5.86 in ADH,DCIS, MDC and IDC (NOS), respectively ( P ＜0.05), while that of FⅧwas 10.60 ±8.99, 16.60 ±3.47,16.90 ±5.62 and 17.90 ±5.62, that of CD31 was 6.80 ±3.90, 19.40 ±4.58, 20.74 ±6.67 and 22.74 ±6.67, and that of CD34 was 14.40 ±12.82,25.20 ±5.39,26.32 ±4.89 and 40.32 ±4.89.

Conclusions

To assess the expression of new vessels in the progression of breast carcinoma, MVD detected by CD105 maybe more valuable, it will provide theoretical evidence for the clinical application of anti-vessel inhibitor.